Prof._nelson_varela.png_thumb90

Nelson Miguel Varela Figueroa

Académico

UNIVERSIDAD DE CHILE

Santiago, Chile

Líneas de Investigación


FARMACOGENETICA; BIOLOGIA MOLECULAR; ONCOLOGIA

Educación

  •  Bioquímica y Biología Molecular, UNIVERSIDAD DE CHILE. Chile, 2004
  •  Tecnólogo Médico, UNIVERSIDAD DE CHILE. Chile, 1999
  •  Doctor en Ciencias Biomédicas, UNIVERSIDAD DE CHILE. Chile, 2010

Experiencia Académica

  •   Académico Full Time

    UNIVERSIDAD DE CHILE

    Medicina

    Santiago, Chile

    2010 - 2015

  •   Académico Full Time

    UNIVERSIDAD DE CHILE

    Medicina

    Santiago, Chile

    2015 - 2016

  •   Académico Full Time

    UNIVERSIDAD DE CHILE

    Medicina

    Santiago, Chile

    2017 - At present

Experiencia Profesional

  •   Responsable Aseguramiento Calidad / RT-PCR para COVID1919 Part Time

    Laboratorio CQF, Facultad de Medicina, Universidad de Chile

    Santiago, Chile

    2020 - At present

Formación de Capital Humano


Dirección de 6 tesis conducentes al grado de licenciado en el periodo 2013-2016
Actualmente dirijo 2 tesis de pregado y 1 tesis de magister, además de la co-tutoria de una tesis doctoral.



 

Article (66)

Addressing genetic diversity and health inequities: RELIVAF’s proposal for Latin American pharmacogenomic guidelines
Association Between <i>CYP2C9</i> and <i>CYP2C19</i> Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy
Association of OPRM1 and OPRD1 Polymorphisms with Pain and Opioid Adverse Reactions in Colorectal Cancer
Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial
CYP1A1 and GSTM1 genes associated with the risk of developing colorectal cancer: a case-control study in the Lima region of Peru
Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer
Prevalence of GSTM1*0 and CYP1A1*2A (rs4646903) variants in the central Peruvian coastal population: Pilot Study of predictive genetic biomarkers for 4P medicine
Small-RNA sequencing identifies serum microRNAs associated with abnormal electrocardiography findings in patients with Chagas disease
The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population
Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study
Parasite Burden of Trypanosoma cruzi in Whole Blood and Buffy Coat Determined by Real-Time PCR in Individuals with Chronic Chagas Disease
An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean.
Editorial: Pharmacogenetics and pharmacogenomics in Latin America: ethnic variability, new insights in advances and perspectives: a RELIVAFCYTED initiative, Volume II.
Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative
Polymorphism in the pvcrt-o and pvmdr-1 genes of Plasmodium vivax associated with a better prognosis for malaria.
The close interaction between hypoxia‑related proteins and metastasis in pancarcinomas
A new insight for the identification of oncogenic variants in breast and prostate cancers in diverse human populations, with a focus on Latinos
Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
Frequency of <i>CYP1A1*2A</i> polymorphisms and deletion of the <i>GSMT1</i> gene in a Peruvian mestizo population
Frequency of <i>CYP2D6*3</i> and *4 and metabolizer phenotypes in three mestizo Peruvian populations
In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19
NOD1 rs2075820 (p.E266K) polymorphism is associated with gastric cancer among individuals infected with cagPAI-positive H. pylori.
Novel risk associations between microRNA polymorphisms and gastric cancer.
Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy.
Pharmacogenetics-based preliminary algorithm to predict the incidence of infection in patients receiving cytotoxic chemotherapy for hematological malignancies: a discovery cohort.
Preliminary pharmacogenomic-based predictive models of tamoxifen response in hormone-dependent Chilean Breast Cancer patients
Resolvin D1 reduces expression and secretion of cytokines and monocyte adhesion triggered by Angiotensin II, in rat cardiac fibroblasts
Retrospective pharmacogenetic analysis of a pediatric patient under anticoagulant treatment: Clinical case
Smartphone screen testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals
As3MT and GST polymorphisms influencing arsenic metabolism in human exposure to drinking groundwater
Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients
Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer
Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach
IL-6 -572C>G and CARD8 304T>A genetic polymorphisms are associated with the absolute neutrophil count in patients with hematological malignancies under chemotherapy: An application of multilevel models to a preliminary pharmacogenetic study.
Polymorphisms PSCA rs2294008, IL-4 rs2243250 and MUC1 rs4072037 are associated with gastric cancer in a high risk population.
The Current State of MicroRNAs as Restenosis Biomarkers
Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients.
Study of the allelic variants CYP2C9*2 and CYP2C9*3 in the Peruvian mestizo population [Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en población mestiza peruana]
The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis.
The role of phase I and II genetic polymorphisms, smoking, alcohol, and family history in the risk of developing testicular cancer.
Farmacogenética, tabaco, alcohol y su efecto sobre el riesgo de desarrollar cáncer
Clinical applications of pharmacogenomics
Pharmacogenomics of antiretroviral therapy in Latin America
Mitotic Inheritance of mRNA Facilitates Translational Activation of the Osteogenic-Lineage Commitment Factor Runx2 in Progeny of Osteoblastic Cells
Upregulation of rat liver PPARα-FGF21 signaling by a docosahexaenoic acid and thyroid hormone combined protocol
Causal role of oxidative stress in unfolded protein response development in the hyperthyroid state
Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses
Preclinical evaluation of the encelia canescens lam extract: Medicinal properties useful for cancer treatment
Bioequivalence of Acenocoumarol in Chilean Volunteers: an Open, Randomized, Double-Blind, Single-Dose, 2-Period, and 2-Sequence Crossover Study for 2 Oral Formulations
Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: Comparison with caucasian and asian populations
Relative bioavailability of two formulations of rosuvastatin importance in clinical practice Biodisponibilidad relativa de dos formulaciones de rosuvastatina. Importancia en la práctica clínica
A comparative bioavailability study of two formulations of pregabalin in healthy chilean volunteers
Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method
Impaired Cell Cycle Regulation of the Osteoblast-Related Heterodimeric Transcription Factor Runx2-Cbf beta in Osteosarcoma Cells
Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, noalcoholic steatohepatitis obese women
Asociación entre el sistema sanguíneo ABO y los polimorfismos genéticos de enzimas de biotransformación en relación con la susceptibilidad a cancer.
Cytochrome P4501A1 (CYP1A1), glutathione S transferase M1 (GSTM1) polymorphisms and their association with smoking and alcohol consumption as gastric cancer susceptibility biomarkers
Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study
Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrorne P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients
Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: Exploring some gene-gene and gene-environment interactions
Chromatin from two classes of platyhelminthes display both protist H1 and higher eukaryote core histones
Gene-gene and gene-environment interactions as modifier factors of prostatic cancer risk: (a case-only) design study
Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients
Modulation of rat liver cytochrome P450 activity by prolonged red wine consumption
CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people
Ethnic susceptibility to lung cancer: differences in CYP2E1, CYP1A1 and GSTM1 genetic polymorphisms between French Caucasian and Chilean populations

Abstract (2)

Genetic variants and clinical factors affecting the response to 5-fluorouracil-based treatment in Chilean patients with advanced colorectal cancer.
Evaluation of CYP1A1 and GSTM1 as gastric cancer susceptibility biomarkers: Influence of smoking habit and alcohol consumption

BookSection (6)

Pharmacodynamic Polymorphisms
Pharmacogenomics: Basis and Milestones
Pharmacogenomics: Challenges and Future Perspectives
Pharmacogenomics: Genetic Polymorphisms
Pharmacokinetic Polymorphisms
Farmacogenetica de la terapia antiretroviral en pacientes que viven con vih, y situación latinoamericana

ConferencePoster (2)

Pharmacogenetics-based preliminary model improves prediction of infection in patients receiving cytotoxic chemotherapy for hematological malignancies.
GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS AS MODIFIER FACTORS OF PROSTATIC CANCER RISK: “A CASE-ONLY” DESIGN STUDY

Errata (1)

Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses (vol 101, pg 124, 2015)

Letter (1)

Reply to the commentary: Estimating genotype and allele frequencies of the CYP2D6 gene

Proyecto (3)

BIOMARCADORES FARMACOGENÉTICOS DE LA TERAPIA ANTI-RETROVIRAL EN PACIENTES QUE VIVEN CON VIH=> BASES PARA UN DIAGNÓSTICO PRE-TERAPÉUTICO.
IMPROVING TESTICULAR CANCER RISK EVALUATION AND PHARMACOTHERAPY THROUGH PHARMACOGENOMICS
ESTUDIO DE CALIDAD FARMACEUTICA PARA EL DESARROLLO DE UN EXTRACTO COMO MEDICAMENTO ANTINEOPLASICO

Review (3)

Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru
Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs
Cancer pharmacogenetics: Study of genetically determined variations on cancer susceptibility due to xenobiotic exposure
1
Gladys Tapia

Academica

Farmacología Molecular y Clínica

FACULTAD DE MEDICINA UNIVERSIDAD DE CHILE

Santiago, Chile

1
RICARDO MORENO

Profesor Titular

Fisiología

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE, FACULTAD DE CIENCIAS BIOLÓGICAS, DEPTO. DE FISIOLOGÍA

Santiago, Chile

1
Carlos Irarrázabal

Full Professor

Fisiología

Universidad de Los Andes

Santiago, Chile

1
Norbel Galanti

Full Professor

ICBM

UNIVERSIDAD DE CHILE, FACULTAD DE MEDICINA, INSTITUTO DE CIENCIAS BIOMÉDICAS, PROGRAMA DE BIOLOGÍA CELULAR Y MOLECULAR

Santiago, Chile

20
Luis Quinones

PROFESOR TITULAR

ONCOLOGIA BASICO-CLINICA

UNIVERSIDAD DE CHILE

Santiago, Chile

4
Ramón Rodrigo

PROFESOR TITULAR

INSTITUTO DE CIENCIAS BIOMÉDICAS

UNIVERSIDAD DE CHILE, FACULTAD DE MEDICINA, INSTITUTO DE CIENCIAS BIOMÉDICAS, PROGRAMA DE FARMACOLOGÍA MOLECULAR Y CLÍNICA

Santiago, Chile

17
DANTE CACERES

Académico

Programa de Salud Ambiental

ESCUELA DE SALUD PUBLICA, FACULTAD DE MEDICINA, UNIVERSIDAD DE CHILE

SANTIAGO, Chile

79
Nelson Varela

Académico

Oncología Básico-Clínico

UNIVERSIDAD DE CHILE

Santiago, Chile

1
Martín Montecino

Director

Institute of Biomedical Sciences

UNIVERSIDAD ANDRES BELLO

Santiago, Chile

1
JULIO TAPIA

Full Professor

Program of Cellular and Molecular Biology

UNIVERSIDAD DE CHILE

SANTIAGO, Chile

1
Alexander Gamboa

Profesor Asistente

Ciencias del Ambiente

Universidad de Santiago de Chile

Santiago, Chile

2
Jana Stojanova

Profesor Auxiliar

Departamento Preclinicas

Universidad de Valparaíso

Viña del Mar, Chile

2
Carla Miranda

Encargada de estudios Clinicos y preclinicos

Oncología Básico Clínica

Universidad de Chile

Santiago, Chile

1
Viviana Guajardo

Profesor Asistente

Psiquiatria

Universidad de Chile

Santiago, Chile

2
juan cayún

Investigador

Departamento de oncología básico-clínico

Universidad de Chile

Santiago, Chile

1
María Bertoglia

Profesor Adjunto

Escuela de Medicina

Universidad Andrés Bello

Santiago, Chile

1
Marina Leiva

Directora Técnica Unidad de Hemodiálisis

Nefrología

Hospital Intercultural de Nueva Imperial

Nueva Imperial, Chile

1
Berta Cerda

Director

Instituto Nacional del Cáncer

Santiago, Chile

1
Johanna Catalán

Profesor Asistente Regular

Facultad de Medicina y Ciencia

Universidad Central de Chile

Santiago, Chile

1
María Lavanderos

Académica

Universidad Bernardo O'higgins

Santiago, Chile

1
Nancy Farfán

Post-doc.

Farmacología

Universidad de Chile

Santiago, Chile

1
Javier Fernández

Investigador

Fundación COANIQUEM Avances Tecnológicos

Santiago, Chile

3
MARIO GALINDO

Profesor Asociado

Instituto de Ciencias Biomédicas

Universidad de Chile

Santiago, Chile